Peter J. Rix

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

Nicola J. Clegg, John Wongvipat, James D. Joseph et al. · Cancer Research · 2012 · 646 citations

Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

Dana E. Rathkopf, Michael J. Morris, Josef J. Fox et al. · Journal of Clinical Oncology · 2013 · 259 citations · Full text

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Andiliy Lai, Mehmet Kahraman, Steven P. Govek et al. · Journal of Medicinal Chemistry · 2015 · 244 citations · Full text

Breast Oncology, Chemoprevention Strategy, Pharmacotherapy +16

Metal enrichment in bauxites by deposition of chemically mature aeolian dust

George H. Brimhall, Christopher J. Lewis, Jay J. Ague et al. · Nature · 1988 · 209 citations

Materials Science, Engineering, Trace Element Geochemistry +7

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

James D. Joseph, Beatrice Darimont, Wei Zhou et al. · eLife · 2016 · 117 citations · Full text

Diverse Models, Breast Oncology, Erα Signaling +16